KLI

Modified bismuth quadruple therapy with low-dose metronidazole as first-line therapy for Helicobacter pylori infection

Metadata Downloads
Abstract
Background: Bismuth-containing quadruple therapy is an effective alternative first-line therapy for Helicobacter pylori infection. We evaluated the efficacy and safety of a modified twice-a-day bismuth quadruple regimen (BQT-2) with low-dose (1000?mg total) metronidazole as first-line therapy for the eradication of H?pylori. Materials and Methods: In this prospective pilot study, patients diagnosed with H?pylori infection and naive to eradication therapy were included. The modified BQT-2 therapy consisted of rabeprazole 20?mg, amoxicillin 1?g, metronidazole 500?mg, and tripotassium dicitrato bismuthate 600?mg (elemental bismuth 240?mg) twice daily, given 30?minutes before morning and evening meals for 14?days. H?pylori eradication was assessed by
Author(s)
피규영최기돈공은정나희경안지용이정훈정기욱김도훈송호준이진혁정훈용
Issued Date
2021
Type
Article
Keyword
Antibacterial agentsantibiotic resistanceCare and treatmentDosage and administrationDrug resistance in microorganismseradicationEvaluationHealth aspectsHelicobacter infectionsHelicobacter pyloriMedical researchExperimentalMetronidazolePatient complianceSkin diseasesUrea
DOI
10.1111/hel.12759
URI
https://oak.ulsan.ac.kr/handle/2021.oak/6973
https://ulsan-primo.hosted.exlibrisgroup.com/primo-explore/fulldisplay?docid=TN_cdi_proquest_miscellaneous_2455844477&context=PC&vid=ULSAN&lang=ko_KR&search_scope=default_scope&adaptor=primo_central_multiple_fe&tab=default_tab&query=any,contains,Modified%20bismuth%20quadruple%20therapy%20with%20low-dose%20metronidazole%20as%20first-line%20therapy%20for%20Helicobacter%20pylori%20infection&offset=0&pcAvailability=true
Publisher
HELICOBACTER
Location
오스트리아
Language
영어
ISSN
1083-4389
Citation Volume
26
Citation Number
1
Citation Start Page
0
Citation End Page
0
Appears in Collections:
Medicine > Medicine
공개 및 라이선스
  • 공개 구분공개
파일 목록
  • 관련 파일이 존재하지 않습니다.

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.